CHICAGO--(BUSINESS WIRE)--CytoCore, Inc. (OTCBB:CYCR) today announced that it has begun three “marketing confirmation” trials for the e2 Collector™ cervical cell collection device. These trials will compare the performance between the e2 Collector and the standard spatula/brush combination for 650 women with moderate to high-grade cervical lesions, and will determine patient and physician satisfaction.
